ABIVAX Announces Its Financial Calendar for 2017

PARIS--(BUSINESS WIRE)--

Regulatory News:

ABIVAX (Paris: ABVX) (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today provides its planned financial calendar for 2017, which is set as follows:

Date			Announcement
Wednesday March 15, 2017			Publication of 2016 Financial Statements
Friday April 28, 2017			Publication and Release of the Annual Financial Report
Friday June 23, 2017			Annual Shareholders Meeting
Wednesday September 20, 2017			Publication of Financial Statements as of June 30, 2017
Friday September 29, 2017			Publication and Release of 2017 Half Year Report

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.abivax.com/en).

About ABIVAX (www.abivax.com)ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials for providing a functional cure for patients with HIV/AIDS. It is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).

More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20161219005714/en/

ABIVAX
Finance
Alain Chevallier, +33 1 53 83 08 41
[email protected]
or
Communication Agency
ALIZE RP
Caroline Carmagnol/Margaux Pronost
+33 6 64 18 99 59 / +33 1 44 54 36 65
[email protected]
or
LifeSci Advisors
Chris Maggos, +41 79 367 6254
[email protected]

Source: ABIVAX

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
• BlockDAG Gives Buyers 25M BDAG for $500 at $0.00002 While Dogecoin Price Holds at $0.068 & Sui Price Eyes Recovery
• QWebDevelopments CEO Anthony Q Purchases Iconic GT at 29, Bringing His Success Full throttle